Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.

Peptides

Neurodegeneration Unit, Basic Medical Sciences, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK.

Published: October 2010

Alzheimer's disease (AD) is a devastating degenerative disorder of the brain for which there is no cure or effective treatment. There is much evidence to suggest that β-amyloid protein (Aβ) aggregation in the brain leading to deposits is an important step in the development of AD. Recently, two peptides, RGKLVFFGR (OR1) and RGKLVFFGR-NH(2) (OR2) containing the sequence KLVFF, which is the central region (residues 16-20) of Aβ, have been found to be potent inhibitors of Aβ aggregate formation. Here we report that retro-inversion of these sequences increases efficacy of the peptides in the inhibition of aggregation and toxicity of β-amyloid. We describe the synthesis and inhibitory properties of these retro-inverso peptides.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2010.06.033DOI Listing

Publication Analysis

Top Keywords

retro-inverso peptides
8
alzheimer's disease
8
development retro-inverso
4
peptides
4
peptides anti-aggregation
4
anti-aggregation drugs
4
drugs β-amyloid
4
β-amyloid alzheimer's
4
disease alzheimer's
4
disease devastating
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!